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Abstract The structural basis of p-opioid receptor (OPR) for 
the specificity in its ligand binding was investigated using chimeric 
/d6-OPRs. Replacement of the region around the first extracel- 
lular loop of 6-OPR with the corresponding region of p-OPR 
gave the resultant chimeric receptor the similar affinity to 
DAMGO compared with the native p-OPR. The reciprocal re- 
placement deprived the high affinity to DAMGO from p-OPR. 
These results indicate that the difference(s) in the structure 
around the first extracellular loop is critical for DAMGO to 
distinguish between p- and ~-OPRs. Furthermore, displacement 
studies revealed that this region is partly involved in the discrim- 
ination between p- and ~-OPRs by other peptidic p-selective 
ligands, such as dermorphin, morphiceptin and CTOP, but not by 
non-peptidic ligands, such as morphine and naloxone. 
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enable us to investigate he structural basis for subtype specific- 
ity of the OPRs in their ligand bindings using the various 
molecular biological techniques. The construction of chimeric 
OPRs is thought o be one of the very powerful approaches to 
the issue, as it has been demonstrated in the cases of adrenaline 
[4-6], acetylcholine [7], dopamine [8] and tachykinin [9,10] re- 
ceptors. In the present study, to elucidate the regions ofp-OPR 
which are specifically recognized by g-selective opioid ligands, 
we have constructed chimeric m/8-OPRs and examined their 
affinities to [3H]DAMGO, one of the most popular g-selective 
opioid ligands, by Scatchard analyses. In addition, other g- 
selective opioid ligands, that is, dermorphin, morphiceptin, 
CTOP, morphine and naloxone, were tested in displacement 
studies with [3H]DAMGO and [3H]DPDPE. 
2. Materials and methods 
1. Introduction 
Endogenous opioid peptides and opiate drugs like morphine 
produce various physiological and pharmacological effects, 
such as analgesia, respiratory depression, euphoria nd modu- 
lations of neuroendocrine, through their specific receptors. Al- 
though pharmacological studies have defined three subtypes of 
opioid receptors (OPRs), that is, g-, 5- and I¢-OPRs, using 
various subtype-specific ligands, the molecular basis for how 
these ligands discriminate among three subtypes of OPRs is yet 
unknown and of great interest. 
Recently we and other groups have cloned these OPR 
cDNAs from the rat brain [1-3]. The amino acid sequences of
the three OPRs are highly conserved in the putative transmem- 
brane domains and the intracellular regions, and the amino acid 
identities in those regions are 73.1-76.3% and 62.3-74.3%, re- 
spectively. On the other hand, the sequences ofthe extracellular 
regions are considerably different (34.1-39.6% of identities), 
and it is likely to assume that the differences in these regions 
are responsible for the discrimination by the subtype-specific 
opioid ligands. The cloning of cDNAs for these OPRs has 
*Corresponding author. Fax: (81) (75) 753 4586. 
Abbreviations." CTOP, o-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2; 
DAMGO, [o-Ala, MePhe 4, Gly(ol)5]enkephalin; DPDPE, [D- 
Pen2'5]enkephalin; EL, extracellular loop; G-protein, GTP binding pro- 
tein; OPR, opioid receptor; TM, transmembrane domain. 
2.1. Materials 
[Tyrosyl-3,5-3H(N)]DAMGO (50.5 Ci/mmol), (-)-[9-3H(N)]brema - 
zocine (29.8 Ci/mmol) and [Tyrosyl-2,6-3H(N)]DPDPE (46.0 Ci/mmol) 
were obtained from DuPont-New England Nuclear (USA). DAMGO 
was purchased from Cambridge Research Biochemicals, Ltd. (UK). 
Morphine hydrochloride was from Takeda Chemical Industries, LTD 
(Japan). Naloxone hydrochloride was from Sigma Chemical Co. 
(USA). Dermorphin, morphiceptin and CTOP were from Peninsula 
Laboratories, INC. (USA). 
2.2. Construction of chimeric receptors 
The chimeric receptors between/2- and ~-OPRs were constructed by 
using the AflIII and BbsI sites which intrinsically exist at the corre- 
sponding position of both receptor cDNAs (Fig. 1). The appropriate 
restriction enzyme fragments of the/2- and ~-OPRs were ligated and 
cloned into the HindIII-ApaI site of the pcDNA3 expression vector 
(Invitrogen, USA). The sequence ofeach construct was confirmed by 
sequencing analysis using Sequenase v r.2 DNA sequencing kit(United 
States Biochemical, USA). Each constructed chimeric receptor was 
given a name on the basis of the origins of its four extracellular do- 
mains. 
2.3. Expression of native and chimeric receptors and binding assay 
For transient expression of the native and chimeric OPRs, each 
plasmid cDNA was transfeeted to COS-7 cells by the DEAE-dextran 
method [11]. After cultivation for 65 h, the cells were harvested and 
homogenized in the following buffer; 50 mM Tris (pH 7.4), 10 mM 
MgCI z and 1 mM EDTA. After centrifugation for 20 min at 30,000 × g, 
the pellet was resuspended in the same buffer. Binding experiments for
Scatchard analyses were performed with various concentrations of 
[3H]DAMGO or [3H]bremazocine. For displacement studies, various 
concentrations of unlabeled opioid ligands and 1 nM [3H]DAMGO or 
1 nM [3H]DPDPE were used. Non-specific binding was determined in 
the presence of 10/2M unlabeled DAMGO, bremazocine or DPDPE. 
The incubations of membrane with opioid ligands were carried out at 
25 °C for 1 h and terminated by vacuum filtration through GF/C filters 
(Whatman). Then the radioactivity was measured by liquid scintillation 
counting. 
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Fig. 1. Proposed model for membrane topography of the rat B-opioid receptor. Solid circles indicate amino acid residues conserved between p- and 
~-opioid receptors. Branched structures show consensus sequences for potential N-linked glycosylation sites. Noted are the unique restriction enzyme 
sites used to construct chimeric receptors. 
2500, A C 
~" 1500- 
1000- 
0 
0 
2000. 
~ le~O. 
1600. 
.~  121111- 
"0 
e~ 
~-  
200- 
B Oral) 
o 
3H-DAMGO (nM) 
G , ~ ~  p.y.  + ~. 
0.03 
002 t 
0.01 
00,51 1.522.533.544.55 
S (fmol) 
3H-DAMGO (nM) 
c 
O~ 
m 
U 
O~ 
2(300- 
1800, 
1600. 
1400, 
1200, 
1000, 
800. 
e00. 
400. 
200- 
0 
0.05- 
~ 0=- 
0.02- 
0.01 - 
tt++~+++ 
~IP  ~,',~ "Js¢ "////, 
ol 
B (fmol) 
3H-DAMGO (nM) 
2000- A 
18oo- 
2 
0.. 1600- 
1400- 
E 
~ 12oo- 
cO 
o 
DDMM 
0.05 
0'04 1 ~ . 3
0.~ 
0.01 
00.511.522.533.544.55 
B (fmol) 
3H-DAMGO (nM) 
T Onogi et al./FEBS Letters 357 (1995) 93-97 95 
A 
C 
O~ 
E 
E 
O.  
=5 e.- 
ifi 
o 
0') 
MDDD 
1800-  
1600-  
1400-  
1200-  
1000-  
800-  
600-  
200-  
0 I 
0.0~ ¢ 
t 0.01 .--.R 0 l i  
~o',~ ; l'.S~='.s~31s~,'.~ "~ 
B (fmol) -,~ 
A 
4 ~ ~ ~ ~ ~ 1'o 
3H-DAMGO (nM) 
DMMM 
1000- 
B (~)  
3H-DAMGO (nM) 
2000- 
C 
1800- 
(~. 1600- 
O~ 
E 14oo- 
"0  
c 80o.  
ig 
.~  600-  
~ 
MDMM 
i - -  o=j 
0.02 
0.01 v 
0|  i i J J i i i i i i 
00 .51  1 .522.533.544,55  
B (fmol) !~  
_ r,/) 
1 2 3 , ; ; "} : ~ 1'o 
DMDD 
3000- 
2500° 
2000- 
1500- 
1000- 
500- 
0 
0 
0.07 - • • 
0.06- 
/ .\ 0.00- • 
/ . . . . .  °°i: o ; lb 1;o~ 2; 
1 2 3 4 5 8 7 8 9 10 
3H-DAMGO (nM) 3H-DAMGO (nM) 
Fig. 3. Saturation binding of [3H]DAMGO to the membrane of COS-7 cells which expressed chimeric MDDD, DMMM, MDMM or DMDD 
receptor. Insets how the Scatchard analyses of [3H]DAMGO binding. 
3. Results and discussion 
Firstly, to determine which the first or the latter half of 
/~-OPR is important to its high affinity to DAMGO, we con- 
structed two chimeric receptors using restriction enzyme AflIII. 
In native/I-OPR, the K d value for DAMGO was 3.46 + 0.84 
nM (n = 3) (Fig. 2). The chimeric receptor MMDD, in which 
the carboxy-terminal h lf of the/~-OPR was replaced with the 
corresponding region of ~-OPR, exhibited an equivalent affin- 
ity (Kd = 2.13 + 0.40 nM; n = 3) to DAMGO compared with 
the native p-OPR, while the reciprocal chimeric receptor 
DDMM poorly bound [3H]DAMGO and the Kd value could 
not be determined as in the case of the native ~-OPR. These 
results uggest that the first halves of p- and 5-OPRs are critical 
for DAMGO to distinguish between these receptors. 
Secondly, for further clarification of the region responsible 
for selective binding of DAMGO, we constructed four chimeric 
receptors using the restriction enzyme BbsI in addition to 
AflIII. The chimeric receptor DMMM, in which the N-terminal 
and first transmembrane domain (TM-1) of/.t-OPR were re- 
placed with the corresponding region of ~-OPR, exhibited an 
equivalent affinity to DAMGO (Kd = 3.16 + 0.91 nM; n -- 3) 
compared with the native/~-OPR (Fig. 3). Conversely, MDDD 
did not display any specific binding to [3H]DAMGO. On the 
other hand, the chimeric receptor DMDD, in which the seg- 
ment containing the first extracellular loop (EL-l), TM-2 and 
a part of TM-3 of 5-OPR was substituted for the correspond- 
ence of p-OPR, exhibited high affinity to [3H]DAMGO 
(K d = 5.24 + 0.86 nM; n = 3), while the reciprocal chimera 
MDMM did not exhibit the high affinity binding to 
Fig. 2. 3 Saturation binding of [ H]DAMGO to the membrane ofCOS-7 cells which expressed native p- or 8-OPR or chimeric MMDD or DDMM 
receptor. Insets how the Scatchard analyses of [3H]DAMGO binding. 
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Fig. 4. Displacements of the specific binding of [3H]DAMGO to the membrane of COS-7 cells expressing/z- (©) or DMDD (e) receptor and of 
[3H]DPDPE to the membrane xpressing ~- (A) receptor with unlabeled p-selective opioid ligands. 
[3H]DAMGO. Because all of the four chimeric receptors were 
verified to bind [3H]bremazocine with high affinity (data not 
shown), the lack of binding of [3H]DAMGO to chimeric recep- 
tors MDDD and MDMM was not due to low expression of 
these chimeric receptors. These results indicate that the region 
around the EL-1 which containing the EL-l,  TM-2 and a part 
of TM-3 is critical for DAMGO to distinguish between/l- and 
5-OPRs. Although much more differences in the amino acid 
sequences between p- and 6-OPRs are found in the amino- 
terminal, EL-2 and EL-3 than EL-l, these regions are not likely 
to be concerned in the discrimination between these two recep- 
tors by DAMGO. This assumption is partly supported by the 
report which demonstrated that the removal of the amino- 
terminal oflz-OPR did not change the affinity to DAMGO [12]. 
To test whether this region is involved in the selective binding 
of other/~-selective opioid ligands, we carried out the displace- 
ment study using p- and 6-OPRs and chimeric receptor DMDD 
(Fig. 4). [3H]DAMGO was used to label/t- and DMDD recep- 
tors and [3H]DPDPE to label ~-OPR. Ka values of 
[3H]DAMGO to p- and DMDD receptors and of [3H] DPDPE 
to 5-OPR were almost equivalent (3.46 + 0.84 nM at p-OPR, 
5.25 _+ 0.86 nM at DMDD receptor and 3.13 + 0.32 nM at 
5-OPR). Unlabeled DAMGO displaced the binding of the triti- 
ated ligand to P- and DMDD receptors in the same degree, 
while the potency of unlabeled DAMGO to inhibit the specific 
binding of the tritiated ligand to ~-OPR was about 100 times 
lower than to P- and DMDD receptors. Peptidic agonists, der- 
morphin and morphiceptin, and a peptidic antagonist, CTOP, 
showed the moderate affinity to DMDD chimeric receptor, that 
is, the affinity was higher than to ~-OPR but lower than to 
/I-OPR. A non-peptidic agonist, morphine, and a non-peptidic 
antagonist, naloxone, bound to p-OPR with much higher affin- 
ity than to 5-OPR and to DMDD chimeric receptor, and the 
differences in the affinities of these non-peptidic ligands be- 
tween 5-OPR and DMDD receptor were much smaller than 
those in the cases of the peptidic ligands. These results uggest 
that the region around the EL-1 is very critical just for 
DAMGO to distinguish between/~- and &-OPRs, while this 
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region is partly involved in the subtype-specific binding of other 
peptidic g-selective ligands, but not in the discrimination be- 
tween g- and 8-OPRs by non-peptidic ligands. These differ- 
ences in the recognition sites for subtype-specific binding 
between DAMGO and other/,t-selective ligands are not so 
surprising, because it has been reported that the different li- 
gands recognize the different sites of the same receptor in the 
cases of many receptors belonged to the G-protein coupled 
receptor family, such as fl-adrenergic, neurokinin-1 and ~- 
opioid receptors [5,13,14]. 
In this study, using chimeric rn/~-OPRs, we demonstrated 
that the region around the EL-1 plays an important role in the 
discrimination between g- and 8-OPRs by DAMGO. There are 
only seven different amino acid residues between/~- and ~- 
OPRs in the amino acid sequence of this region (Fig. 1), and 
it is likely that one or a few of these amino acid residues are 
responsible for the subtype selectivity of DAMGO. To deter- 
mine which amino acid residue(s) in this region plays a key role 
in the discrimination by DAMGO between g- and 8-OPRs, 
site-directed mutagenesis experiments are now proceeding in 
our laboratory. 
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